# Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population

> **NCT03468309** · — · COMPLETED · sponsor: **Seattle Institute for Biomedical and Clinical Research** · enrollment: 53 (actual)

## Conditions studied

- Pharmacogenetic Testing

## Interventions

- **GENETIC:** Genecept Assay and G-DIG decision tool

## Key facts

- **NCT ID:** NCT03468309
- **Lead sponsor:** Seattle Institute for Biomedical and Clinical Research
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2019-04-01
- **Final completion:** 2024-04-17
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468309, "Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03468309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*